D. E. Shaw & Co., Inc. - GLOBAL BLOOD THERAPEUTICS IN ownership

GLOBAL BLOOD THERAPEUTICS IN's ticker is GBT and the CUSIP is 37890U108. A total of 195 filers reported holding GLOBAL BLOOD THERAPEUTICS IN in Q2 2022. The put-call ratio across all filers is 0.79 and the average weighting 0.4%.

Quarter-by-quarter ownership
D. E. Shaw & Co., Inc. ownership history of GLOBAL BLOOD THERAPEUTICS IN
ValueSharesWeighting
Q3 2022$19,027,000
+102.4%
279,400
-5.0%
0.02%
+109.1%
Q2 2022$9,401,000
+1926.1%
294,245
+2095.5%
0.01%
Q1 2022$464,000
-66.1%
13,402
-71.4%
0.00%
-100.0%
Q4 2021$1,370,000
-16.9%
46,823
-27.6%
0.00%0.0%
Q3 2021$1,648,000
+34.2%
64,656
+128.0%
0.00%0.0%
Q4 2020$1,228,000
-78.4%
28,355
-72.5%
0.00%
-83.3%
Q3 2020$5,680,000
-57.2%
103,022
-51.0%
0.01%
-62.5%
Q2 2020$13,263,000
-28.2%
210,100
-41.9%
0.02%
-44.8%
Q1 2020$18,482,000
+57.0%
361,735
+144.3%
0.03%
+123.1%
Q4 2019$11,772,000
-29.5%
148,100
-57.0%
0.01%
-38.1%
Q3 2019$16,694,000
+174.0%
344,047
+197.0%
0.02%
+162.5%
Q2 2019$6,093,000
+69.4%
115,841
+70.5%
0.01%
+60.0%
Q1 2019$3,596,000
+74.2%
67,923
+35.1%
0.01%
+66.7%
Q4 2018$2,064,000
+169.5%
50,261
+149.4%
0.00%
+200.0%
Q3 2018$766,000
+189.1%
20,150
+266.8%
0.00%
Q1 2018$265,000
-63.2%
5,494
-70.0%
0.00%
-100.0%
Q4 2017$720,000
-62.1%
18,297
-77.8%
0.00%
-66.7%
Q3 2016$1,899,000
+638.9%
82,374
+431.4%
0.00%
Q2 2016$257,000
+0.4%
15,500
-4.0%
0.00%
Q1 2016$256,00016,1420.00%
Other shareholders
GLOBAL BLOOD THERAPEUTICS IN shareholders Q2 2022
NameSharesValueWeighting ↓
GREAT POINT PARTNERS LLC 595,473$25,790,0004.19%
Grace Capital 131,549$5,697,0003.60%
Fernwood Investment Management, LLC 201,657$8,734,0003.44%
Fairmount Funds Management LLC 215,000$9,312,0003.33%
Arctis Global LLC 293,700$12,720,0002.74%
Perceptive Advisors 5,674,711$245,771,0002.64%
ArchPoint Investors 217,510$9,420,0002.61%
Alerce Investment Management, L.P. 126,270$5,469,0002.15%
Profit Investment Management, LLC 42,196$1,826,0001.17%
Affinity Asset Advisors, LLC 50,000$2,166,0001.15%
View complete list of GLOBAL BLOOD THERAPEUTICS IN shareholders